Cytokine/chemokine elevation during the transition phase from HSV encephalitis to autoimmune anti-NMDA receptor encephalitis

Dalmau, 2011, Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis, Lancet Neurol, 10, 63, 10.1016/S1474-4422(10)70253-2 Armangue, 2014, Herpes simplex virus encephalitis is a trigger of brain autoimmunity, Ann Neurol, 75, 317, 10.1002/ana.24083 Kothur, 2017, Cerebrospinal fluid cyto-/chemokine profile during acute herpes simplex virus induced anti-N-methyl-d-aspartate receptor encephalitis and in chronic neurological sequelae, Dev Med Child Neurol, 59, 806, 10.1111/dmcn.13431 Florance, 2009, Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents, Ann Neurol, 66, 11, 10.1002/ana.21756 Titulaer, 2013, Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study, Lancet Neurol, 12, 157, 10.1016/S1474-4422(12)70310-1 Goenka, 2017, Extended clinical spectrum of anti-N-methyl-d-aspartate receptor encephalitis in children: a case series, Pediatr Neurol, 72, 51, 10.1016/j.pediatrneurol.2017.03.010 Nosadini, 2017, Herpes simplex virus-induced anti-N-methyl-d-aspartate receptor encephalitis: a systematic literature review with analysis of 43 cases, Dev Med Child Neurol, 59, 796, 10.1111/dmcn.13448 Leypoldt, 2015, Investigations on CXCL13 in anti-N-methyl-d-aspartate receptor encephalitis: a potential biomarker of treatment response, JAMA Neurol, 72, 180, 10.1001/jamaneurol.2014.2956 Hachiya, 2013, Rituximab ameliorates anti-N-methyl-d-aspartate receptor encephalitis by removal of short-lived plasmablasts, J Neuroimmunol, 265, 128, 10.1016/j.jneuroim.2013.09.017 Allison, 2000, Mycophenolate mofetil and its mechanisms of action, Immunopharmacology, 47, 85, 10.1016/S0162-3109(00)00188-0